oral glp-1 agonist brand name A medication you swallow — no needle, no food restrictions — just had its first head-to-head trial results published. Orforglipron (Foundayo, Eli Lilly) was FDA-approved April 2026. In July 2026, the Quantity:Double-Pack ($69) hidden-from-search The rapid rise of

oral glp-1 agonist brand name A medication you swallow — no needle, no food restrictions — just had its first head-to-head trial results published. Orforglipron (Foundayo, Eli Lilly) was FDA-approved April 2026. In July 2026, the Quantity:Double-Pack ($69) hidden-from-search The rapid rise of

The rapid rise of GLP-1 receptor agonists presents a complex dilemma for clinicians managing patients with eating disorders. While these medications show potential in reducing binge eating behaviors by targeting brain reward

doi: 10.1111/dom.16077

hidden-from-search

Quantity:Double-Pack ($69)

A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease